ISIS-APO: Phase II data

A double-blind, international Phase II trial in 65 patients with high (>=50 mg/dL and <175 mg/dL) or very high (>=175 mg/dL) LPA levels showed that once-weekly 100-300 mg doses of subcutaneous ISIS-AP...